Wyniki wyszukiwania:

Immunotherapy has emerged as a promising modality in the treatment of Oral Squamous Cell Carcinoma (OSCC), particularly for advanced and recurrent cases. Unlike conventional therapies, which target the tumor directly, immunotherapy harnesses the body's immune system to recognize and destroy cancer cells. The most widely studied approach in OSCC involves immune checkpoint inhibitors targeting the PD-1/PD-L1 axis. Drugs like nivolumab and pembrolizumab have demonstrated improved survival rates in patients with recurrent or metastatic OSCC, especially those with PD-L1 expression.Combining...

Immunotherapy has emerged as a promising treatment modality for oral squamous cell carcinoma (OSCC), especially in advanced and recurrent cases where conventional therapies offer limited survival benefits. By harnessing the body's immune system, immunotherapeutic approaches such as immune checkpoint inhibitors-particularly anti-PD-1 agents like nivolumab and pembrolizumab-have shown improved overall survival and quality of life in select OSCC patients, as demonstrated in landmark trials like KEYNOTE-048 and CheckMate 141. Other strategies, including cancer vaccines, adoptive cell therapy,...